Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Solid Tumors · Pancreatic Cancer · MREO

MEREO BIOPHARMA GROUP

Mereo BioPharma Group plc

MEREO BIOPHARMA GROUP trial registry — 51 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
Status
Public
HQ
4TH FLOOR, ONE, LONDON, USA
Employees
4
Programs
47
Drugs
22
Patents
18
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

MEREO BIOPHARMA GROUP clinical trials

Registry index of 51 ClinicalTrials.gov studies linked to MEREO BIOPHARMA GROUP programs — each row shows trial ID, program name, phase, status, and indication.

MEREO BIOPHARMA GROUP trial registry — 51 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for MEREO BIOPHARMA GROUP.

  1. Vantictumab combined with paclitaxel — Phase 1

    Clinical update

  2. Placebo Oral Tablet — Phase 2

    Clinical update

  3. OMP-54F28, Paclitaxel and Carboplatin — Phase 1

    Clinical update

  4. OMP-54F28, Nab-Paclitaxel and Gemcitabine — Phase 1

    Clinical update

  5. Alvelestat (MPH966) — Phase 2

    Clinical update

  6. Active treatment with a high dose of BGS649 — Phase 2

    Clinical update

  7. Vantictumab — Phase 1

    Clinical update

  8. setrusumab — Phase 2

    Clinical update

Trial registry

51 studies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.